Everything is made with a smile and with you in mind. All of our characters and products are made from scratch. This is clearly illustrated by experience with the development of cancer immunotherapy for lymphoma, in which previously limited success using anti-idiotypic monoclonal antibodies has progressed to more promising cell-mediated therapies using T cells and dendritic cells ( Houot & Levy, 2009).Ī critical look at efforts over the past 40 years, together with the replacement of commercial gain, ego and fashion as the primary drivers of research, should ensure that our renewed efforts are not futile yet again in the war against this devastating disease.Welcome to the Savvyy Character Company! Here you’re not just a fan, you are part of the story. Similarly, the resurrected commercial potential of therapeutic antibodies ( Nelson et al, 2010) should not make us ignore the hard-learned lessons of cancer immunology: that cell-mediated immunity is more potent against tumours than is humoral immunity ( Palucka et al, 2011). Surely, this would simply repeat the last 40 years with yet more publications and no progress in actual therapy. Thus, unless individually defined (multi-)genetic therapy suddenly becomes technically and economically viable, we need to ask how much value there is in simply cataloguing yet more mutations. Maybe we should thus take a moment to reflect on the shortcomings of the previous 40 years, to avoid repeating the same errors and to prevent our efforts from being futile again.įor example, recent progress on the sequencing of cancer genomes ( Stratton et al, 2009) reinforces the concept that all cancers are genetically individual ( Greenman et al, 2007). However, as you point out, despite the voluminous amount of published knowledge, we are still waiting for substantial progress in actual therapy.
In your recent editorial about the 40th anniversary of Nixon's war on cancer ( Jacobs, 2011) you correctly argue for continuing the effort and funding to defeat cancer.
0 kommentar(er)
